Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease

“The MK-1654-004 study evaluated a broad spectrum of RSV disease ranging from mild outpatient illness to severe disease requiring hospitalization. These promising results demonstrating decreased incidence of RSV disease, including hospitalizations, highlight the potential for clesrovimab to play an important role in helping to alleviate the continued burden of RSV on infants and their families.”

“So let me start with why is this important? You know, it's important because we are talking about a uniquely vulnerable population. That's to say, children under two years of age with chronic lung disease, congenital heart disease, or other conditions that put them at increased risk for severe RSV disease when they're entering that second RSV season.”

“For some children, the potentially serious impact of RSV does not stop after their first RSV season. The recent FDA and EMA regulatory filings represent important opportunities to help expand protection with Enflonsia for vulnerable children under two years of age during their second RSV season.”